Drug Profile
Research programme: campylobacter vaccine - AVANT
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Developer Celldex Therapeutics Inc
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Campylobacter infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Campylobacter-infections in USA (PO)
- 27 May 2008 This vaccine is still in active development
- 09 Aug 2006 This vaccine is still in active development